natgillin/translations-raw huggingface dataset:
This was based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and fertility.
To je bilo ugotovljeno na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih se odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja.
In addition, rosiglitazone inhibited ovarian oestradiol and progesterone synthesis and lowered plasma levels of these hormones resulting in effects on oestrus/menstrual cycles and fertility (see section 4.4).
Poleg tega je rosiglitazon zavrl sintezo estradiola in progesterona v jajčnikih in znižal koncentracijo teh hormonov v plazmi, kar je vplivalo na estrus/menstruacijske cikluse in plodnost (glejte poglavje 4.4).
If risk factors for hypoglycaemia are present (including renal insufficiency, low body weight, malnourishment, co-administration with certain other medicinal products (see section 4.5) or if the patient's life-style changes) it may be necessary to revert to concomitant therapy and down titrate the glimepiride dose.
Če so prisotni dejavniki tveganja za hipoglikemijo (vključno z insuficienco ledvic, nizko telesno maso, nezadostno prehranjenostjo, sočasno uporabo določenih drugih zdravil (glejte poglavje 4.5) ali če se bolnikov način življenja spremeni) utegne biti potrebna vrnitev na sočasno terapijo in zmanjšanje odmerka glimepirida.
In an animal model for familial adenomatous polyposis (FAP), treatment with rosiglitazone at 200 times the pharmacologically active dose increased tumour multiplicity in the colon.
V živalskem modelu familiarne adenomatozne polipoze (FAP) je uporaba rosiglitazona v 200-kratniku farmakološko aktivnega odmerka povečala število tumorjev v kolonu.
• if you have had diabetic ketoacidosis (a complication of diabetes causing rapid weight
• če imate diabetično ketoacidozo (zaplet sladkorne bolezni s hitrim hujšanjem, siljenjem
The incidence of all adverse events relating to liver and biliary systems was < 1.5% in any treatment group and similar to placebo.
Incidenca vseh neželenih pojavov, povezanih s hepatobiliarnim sistemom, je bila v vseh zdravljenih skupinah < 1,5 % in podobna, kot pri placebu.
Studies on embryofoetal development and pre-and postnatal development revealed eye malformations, skeletal anomalies, abortions, and an increased foetal death rate.
Študije embriofetalnega razvoja ter pred- in ponatalnega razvoja so pokazale malformacije oči, anomalije okostja, splave in večjo umrljivost plodov.
There are no adequate data from the use of either active substance (rosiglitazone and glimepiride) in pregnant women.
Ni zadostnih podatkov o uporabi ene ali druge zdravilne učinkovine (rosiglitazona ali glimepirida) pri nosečnicah.
• if you are allergic (hypersensitive) to rosiglitazone, glimepiride, or any of the other ingredients of Avaglim (listed in Section 6), or to other medicines called sulphonylureas
• če ste alergični na (preobčutljivi za) rosiglitazon, glimepirid ali katerokoli drugo sestavino zdravila Avaglim (navedene v poglavju 6), ali na zdravila imenovana sulfonilsečnine (npr.
Like all medicines, Avaglim can cause side effects, but not everybody gets them.
Kot vsa zdravila ima lahko tudi zdravilo Avaglim neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Many medicines (or alcohol) can affect the way Avaglim controls the amount of sugar in your blood.
Nekatera zdravila (ali alkohol) lahko še posebej vplivajo na način kako zdravilo Avaglim uravnava vrednost krvnega sladkorja.
Very rare impairment of liver function (e.g. with cholestasis and jaundice)
Zelo redki okvara delovanja jeter (npr. s holestazo in zlatenico)
Based on the experience with glimepiride and with other sulphonylureas the following interactions
Na podlagi izkušenj z glimepiridom in drugimi sulfonilsečninami je treba omeniti naslednja medsebojna
This leads to a release of insulin by exocytosis.
To povzroči sprostitev insulina z eksocitozo.
• if you have had a heart attack or severe angina, that's being treated in hospital
• če ste doživeli srčni napad ali imate hudo angino pektoris in ste se zaradi tega zdravili v
• reduction in blood count (anaemia) low numbers of white blood cells (leucopaenia) and blood cells needed for blood clotting (thrombocytopaenia)
• zmanjšanje števila krvnih celic (anemija) nizke vrednosti belih krvničk (levkopenija) in krvnih celic potrebnih za strjevanje krvi (trombocitopenija)
AVAGLIM is not indicated for combination use with metformin and therefore should not be used in
AVAGLIM ni indiciran za kombinirano uporabo z metforminom, zato ga ne smete uporabljati v tritirni
(monotherapy or dual oral therapy).
(monoterapija ali peroralno zdravljenje z dvema zdravilnima učinkovinama).
The major routes of metabolism are N-demethylation and hydroxylation, followed by conjugation with sulphate and glucuronic acid.
Glavni poti presnove sta N-demetilacija in hidroksilacija, ki jima sledi konjugacija s sulfatom in glukuronsko kislino.
The contribution of the major metabolite (a para-hydroxy-sulphate) to the overall antihyperglycaemic activity of rosiglitazone has not been fully elucidated in man and it cannot be ruled out that the metabolite may contribute to the activity.
Prispevek glavnega presnovka (parahidroksisulfata) k celotnemu antihiperglikemičnemu delovanju rosiglitazona pri človeku ni povsem razjasnjen in ni mogoče izključiti, da ta presnovek pripomore k delovanju.
The following statements reflect the pharmacokinetic properties of the individual components of
Naslednje navedbe temeljijo na farmakokinetičnih lastnostih posameznih sestavin AVAGLIMA.
Hospitalisation should be considered as appropriate.
Zaradi tega je ustrezen ukrep hospitalizacija.
Since there is no significant in vitro inhibition of CYP1A2, 2A6, 2C19, 2D6, 2E1, 3A or 4A with rosiglitazone, there is a low probability of significant metabolism-based interactions with substances metabolised by these P450 enzymes.
Rosiglitazon in vitro ne zavira pomembno CYP1A2, 2A6, 2C19, 2D6, 2E1, 3A ali 4A, tako da obstaja le majhna verjetnost za pomembne presnovno pogojene interakcije s snovmi, ki se presnavljajo s temi encimi P450.
Administration of rosiglitazone with food resulted in no change in overall exposure (AUC), although a small decrease in Cmax (approximately 20-28%) and a delay in tmax (approximately 1.75 h) were observed compared to dosing in the fasted state.
Uporaba rosiglitazona s hrano ni spremenila celotne izpostavljenosti (AUC), zabeležili pa so majhno zmanjšanje Cmax (približno 20-28 %) in zapoznitev tmax (približno 1,75 ure) v primerjavi z uporabo na tešče.
Both rosiglitazone and glimepiride have been detected in the milk of experimental animals.
Tako rosiglitazon kot glimepirid so odkrili v mleku poskusnih živali.
AVAGLIM may be used to substitute concomitant sulphonylurea and rosiglitazone in established dual oral therapy providing the patient has achieved at least half-maximum dose of sulphonylurea.
AVAGLIM je mogoče uporabiti kot zamenjavo za sočasno uporabo sulfonilsečnine in rosiglitazona v utečeni dvotirni peroralni terapiji, če je bolnik dosegel vsaj polovični največji odmerek sulfonilsečnine.
The symptoms may be delayed for up to 24 hours after ingestion.
Simptomi se lahko pojavijo z zamikom do 24 ur po zaužitju.
The MAH commits to performing the studies and additional pharmacovigilance activities detailed in the Pharmacovigilance Plan, as agreed in version 4 of the Risk Management Plan (RMP) presented in Module 1.8.2. of the Marketing Authorisation and any subsequent updates of the RMP agreed by the
Imetnik dovoljenja za promet z zdravilom se obvezuje, da bo izvedel študije in dodatne farmakovigilančne aktivnosti, podrobno opisane v načrtu farmakovigilance, ki je bil sprejet v različici 4 načrta za obvladovanje tveganja (RMP), predstavljenem v modulu 1.8.2. vloge za pridobitev dovoljenja za promet z zdravilom in vseh nadaljnih posodobitvah načrta za obvladovanje tveganja v soglasju z Odborom za zdravila za uporabo v humani medicini (CHMP).
6 Cross-allergenicity with sulphonylureas, sulphonamides or related substances is possible.
6 Možna je navzkrižna preobčutljivost s sulfonilsečninami, sulfonamidi in sorodnimi učinkovinami.
Rare Rare Rare Rare Rare Rare Rare
Zelo redki Zelo redki Zelo redki Zelo redki Zelo redki Zelo redki
Women who are infertile due to a condition affecting their ovaries (such as Polycystic Ovarian Syndrome), may start ovulating again when they start taking Avaglim.
Pri ženskah, ki so zaradi bolezni jajčnikov (kot je sindrom policističnega jajčnika) neplodne, se lahko po začetku jemanja zdravila Avanglim ponovno pojavi ovulacija.
The other ingredients are: sodium starch glycollate (Type A), hypromellose (E464), microcrystalline cellulose (E460), lactose monohydrate, magnesium stearate, titanium dioxide (E171), macrogol 400,
Pomožne snovi so: natrijev karboksimetilškrob (vrsta A), hipromeloza (E464), mikrokristalna celuloza (E460), laktoza monohidrat, magnezijev stearat, titanov dioksid (E171), makrogol 400, črni in/ali rdeči
The following data are findings in studies performed with rosiglitazone or glimepiride individually.
Naslednji podatki so izsledki študij, narejenih z rosiglitazonom oz. glimepiridom posamezno.
In view of the potential for development of heart failure in these patients, rosiglitazone should therefore not be initiated in patients having an acute coronary event and it should be discontinued during the acute
Glede na možno tveganje za pojav srčnega popuščanja pri teh bolnikih, se zdravljenja z rosiglitazonom ne sme uvesti pri bolnikih, ki imajo akutni koronarni dogodek, oziroma je treba zdravljenje med akutno fazo
If ALT levels are increased to >3X upper limit of normal during rosiglitazone therapy, liver enzyme levels should be reassessed as soon as possible.
Če se raven ALT med zdravljenjem z rosiglitazonom zviša na > 3-kratno zgornjo normalno mejo, je treba čim prej znova določiti raven jetrnih encimov.
It reduces glycaemia by reducing insulin resistance at adipose tissue, skeletal muscle and liver.
Glikemijo znižuje z zmanjševanjem odpornosti za insulin v maščobnem tkivu, skeletnih mišicah in jetrih.
Concomitant administration of rosiglitazone with the oral anti-diabetic agents metformin, glimepiride, glibenclamide and acarbose did not result in any clinically relevant pharmacokinetic interactions.
Sočasna uporaba rosiglitazona s peroralnimi antidiabetičnimi zdravili metforminom, glimepiridom, glibenklamidom in akarbozo ni povzročila klinično pomembnih farmakokinetičnih interakcij.
All patients, particularly those receiving concurrent insulin therapy, those at risk for heart failure and those with reduced cardiac reserve, should be monitored for signs and symptoms of adverse reactions relating to fluid retention, including weight gain and heart failure.
Vse bolnike, še posebej pa bolnike, ki se sočasno zdravijo z insulinom, bolnike pri katerih obstaja tveganje srčnega popuščanja in bolnike z zmanjšano srčno rezervo, je treba nadzirati glede pojava znakov in simptomov neželenih učinkov, povezanih z zastajanjem tekočine, vključno s povečanjem telesne mase in srčnim popuščanjem.
WHAT AVAGLIM IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO AVAGLIM IN ZA KAJ GA UPORABLJAMO
For this reason, other medicines should only be taken with the knowledge (or at the prescription) of the doctor.
Zato smejo bolniki druga zdravila jemati le z zdravnikovo vednostjo ali po njegovem navodilu.
Glimepiride is metabolized by cytochrome P450 2C9 (CYP2C9).
Glimepirid se presnavlja s citokromom P450 2C9 (CYP2C9).
quinolone antibiotics, probenecid, miconazol, pentoxifylline (high dose parenteral), tritoqualine, fluconazole.
kinolonski antibiotiki, probenecid, mikonazol, pentoksifilin (velik parenteralen odmerek), tritokalin, flukonazol.
Very rare Very rare
Zelo redki Zelo redki
After intravenous dosing in patients, no significant biliary excretion of glimepiride or its M1 metabolite was observed.
Po intravenski uporabi pri bolnikih niso ugotovili pomembnega biliarnega izločanja glimepirida ali presnovka M1.
For AVAGLIM no preclinical or clinical data on exposed pregnancies or lactation are available.
Za AVAGLIM ni na voljo predkliničnih ali kliničnih podatkov o nosečnostih ali dojenju med
Preclinical effects were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use or were caused by the pharmacodynamic effect (hypoglycaemia) of the substance.
Predklinično so učinke glimepirida opazili samo pri izpostavljenosti, ki je močno presegala največjo izpostavljenost pri človeku, kar kaže na majhen pomen za klinično uporabo, ali jih je povzročil njegov farmakodinamični učinek (hipoglikemija).
Patients unable to achieve glycaemic control on at least half-maximum dose of other sulphonylurea monotherapy (except chlorpropamide, see section 4.4).
Bolniki, ki ne morejo doseči urejenosti glikemije z vsaj polovico največjega odmerka druge sulfonilsečnine v monoterapiji (razen klorpropamida, glejte poglavje 4.4).
Avaglim and other medicines for diabetes can make some existing conditions worse, or cause serious side effects.
Zdravilo Avanglim in druga zdravila za zdravljenje sladkorne bolezni lahko poslabšajo nekatera že obstoječa bolezenska stanja ali povzročijo hude neželene učinke.
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked.
Če se pojavijo simptomi, ki nakazujejo moteno delovanje jeter - med takšnimi so lahko nepojasnjena navzeja, bruhanje, bolečine v trebuhu, utrujenost, anoreksija in/ali temen urin - je treba preveriti jetrne encime.
The physiological response to acute physical exercise, a reduction in insulin secretion, is maintained during treatment with glimepiride.
Zmanjšanje izločanja insulina, ki je fiziološki odziv na akutno telesno obremenitev, se med zdravljenjem z glimepiridom ohrani.
Plasma concentrations are approximately dose proportional over the therapeutic dose range.
V območju terapevtskih odmerkov je koncentracija v plazmi približno sorazmerna odmerku.
Therapy with AVAGLIM should not be initiated in patients with increased baseline liver enzyme levels (ALT >2.5X upper limit of normal) or with any other evidence of liver disease.
Terapije z AVAGLIMOM ne smete uvesti pri bolnikih, ki imajo izhodiščno zvišano raven jetrnih encimov (ALT > 2,5-kratna zgornja normalna meja) ali kakšne druge znake bolezni jeter.
Rosiglitazone is a selective agonist at the PPARγ (peroxisome proliferator activated receptor gamma) nuclear receptor and is a member of the thiazolidinedione class of antihyperglycaemic agents.
Rosiglitazon je selektiven agonist jedrnih receptorjev PPARγ (peroksisomski proliferatorski aktivirani receptor gama) in spada med tiazolidindionske antihiperglikemike.
• inflammation of the liver (hepatitis), yellowing of the skin (jaundice)
• vnetje jeter (hepatitis), rumeno obarvanje kože (zlatenica)
Due to the potential for decreased renal function the initiation and maintenance of therapy with AVAGLIM in elderly patients should be under close medical supervision due to an increased susceptibility to hypoglycaemia (see section 4.4).
Pri starejših bolnikih mora uvedba in vzdrževanje terapije z AVAGLIMOM zaradi možnosti zmanjšanega delovanja ledvic potekati pod natančnim zdravniškim nadzorom, ker obstaja večja dovzetnost za hipoglikemijo (glejte poglavje 4.4).
In double-blind clinical trials with rosiglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo (0.2%) and less than that of the active comparators (0.5% metformin/sulphonylureas).
V dvojno slepih kliničnih preskušanjih z rosiglitazonom je bila incidenca zvišanj ALT na več kot trikratno zgornjo normalno mejo enaka kot pri placebu (0,2 %) in manjša kot pri aktivnem primerjalnem zdravilu (0,5 % z metforminom/sulfonilsečninami).
Rare congestive heart failure/pulmonary oedema
Redki kongestivno srčno popuščanje/pljučni edem
The rosiglitazone dose may need to be increased.
Potrebno utegne biti povečanje odmerka rosiglitazona.
Do not use Avaglim after the expiry date shown on the pack.
Zdravila Avaglim ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini.
Take special care with Avaglim Avaglim is not recommended for people aged under 18, as the safety and effectiveness are not known.
Pri bolnikih, mlajših od 18 let, uporaba zdravila Avaglim ni priporočljiva, saj varnost in učinkovitost zdravila pri njih nista znani.
In clinical trials, the glucose lowering effects observed with rosiglitazone are gradual in onset with near maximal reductions in fasting plasma glucose (FPG) evident following approximately 8 weeks of therapy.
V kliničnih preskušanjih se je učinek na znižanje glukoze, opazen z rosiglitazonom, razvil postopoma; skoraj maksimalno znižanje glukoze v plazmi na tešče (GPT) je bilo opazno po približno 8 tednih terapije.
In addition, rosiglitazone was not genotoxic in a battery of in vivo and in vitro genotoxicity studies and there was no evidence of colon tumours in lifetime studies of rosiglitazone in two rodent species.
Poleg tega rosiglitazon ni bil genotoksičen v skupini študij genotoksičnosti in vivo in in vitro; v vseživljenjskih študijah rosiglitazona pri dveh vrstah glodalcev niso ugotovili znakov tumorjev
It is advised that patients established on rosiglitazone and chlorpropamide concomitant therapy should not switch to AVAGLIM as chlorpropamide has a long half-life which may increase the risk of hypoglycaemia.
Bolniki, ki uporabljajo utečeno sočasno terapijo z rosiglitazonom in klorpropamidom, naj ne bi prešli na AVAGLIM, kajti klorpropamid ima dolg razpolovni čas, kar lahko poveča tveganje za hipoglikemijo.
Some medicines used to treat high blood pressure (such as beta-blockers, clonidine, guanethidine or reserpine) may make you less aware of the warning signs of low blood sugar (sweating; fast irregular
Nekatera zdravila za zdravljenje visokega krvnnega tlaka (kot so zaviralci beta, klonidin, gvanetidin ali reserpin) vam lahko zmanjšajo zavedanje o nekaterih opozorilnih znakih nizke vrednosti krvnega sladkorja (znojenje, hitro neredno bitje srca).
There have been no formal interaction studies for AVAGLIM.
Z AVAGLIMOM niso izvedli formalnih študij medsebojnega delovanja.
The tablets are supplied in blister packs containing 14, 28, 56, 84 or 112 film-coated tablets.
Pakiranje vsebuje 14, 28, 56, 84 ali 112 filmsko obloženih
Accumulation of the metabolites in plasma is expected upon repeated dosing, especially that of the major metabolite (a para-hydroxy-sulphate) for which an 8-fold accumulation is anticipated.
Po večkratnem odmerjanju je treba pričakovati kopičenje presnovkov v plazmi, zlasti kopičenje glavnega presnovka (parahidroksisulfata), za katerega je predvideno 8-kratno kopičenje.
M1, but not M2, possesses about 1/3 of the pharmacological activity as compared to its parent in an animal model.
M1 se nato z enim od več citosolskih encimov presnovi v M2. M1, ne pa tudi M2, ima v živalskem modelu v primerjavi z matično spojino približno 1/3 farmakološke aktivnosti.
In very rare cases a fatal outcome has been reported.
V zelo redkih primerih so bolniki umrli.
Metabolism of rosiglitazone is extensive with no parent compound being excreted unchanged.
Rosiglitazon se v veliki meri presnovi in nič matične spojine se ne izloči nespremenjene.
Extrapancreatic effects include an improvement in insulin sensitivity of peripheral tissue and a reduction in hepatic uptake of insulin.
Med zunajpankreatičnimi učinki so izboljšanje občutljivosti za insulin v perifernih tkivih in zmanjšanje
AVAGLIM is contraindicated in patients with severe renal impairment (creatinine clearance less than
AVAGLIM je kontraindiciran pri bolnikih s hudo okvaro ledvic (očistek kreatinina manj kot 30 ml/min,
SmithKline Beecham Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
SmithKline Beecham Ltd, 980 Great West Road, Brentford, Middlesex, TW8 9GS, Velika Britanija.
Closure of the potassium channels leads to depolarisation of the beta cell and results by opening of the calcium channels - to an increased influx of calcium into the cell.
Zaprtje kalijevih kanalčkov povzroči depolarizacijo celic beta in z odprtjem kalcijevih kanalčkov poveča dotok kalcija v celice.
Glimepiride very rapidly increases the number of active glucose transport molecules in the plasma membranes of muscle and fat cells, resulting in stimulation of glucose uptake.
Glimepirid zelo hitro poveča število molekul za aktivni prenos glukoze v plazemskih membranah mišičnih in maščobnih celic; posledica je stimuliran privzem glukoze.
If a patient wishes to become pregnant or if pregnancy occurs, treatment with AVAGLIM should be
Če bolnica želi zanositi ali če zanosi, je treba zdravljenje z AVAGLIMOM prekiniti.
In mechanistic studies, the weight increase was predominantly shown to be due to increased subcutaneous fat with decreased visceral and intra-hepatic
Študije mehanizma so pokazale, da je povečanje telesne mase pretežno posledica povečanja podkožnega maščevja ob zmanjšanju visceralnega in
• fluconazole (used to treat fungal infections).
• flukonazol (uporabljamo ga za zdravljenje glivičnih okužb).
In clinical studies in volunteers rosiglitazone has been administered at single oral doses of up to 20 mg and was well
V kliničnih študijah pri prostovoljcih so ti dobro prenesli rosiglitazon, uporabljen v enkratnih peroralnih odmerkih do 20 mg.
Data from double-blind studies confirm that the safety profile of concomitant rosiglitazone and glimepiride is similar to that of the combined adverse reaction profile for the two active substances.
Podatki dvojno slepih študij potrjujejo, da so varnostne značilnosti skupaj uporabljenega rosiglitazona in glimepirida podobne kombiniranim značilnostim neželenih učinkov obeh zdravilnih učinkovin.
Administration of the 4 mg/4 mg combination with food led to an increase in glimepiride exposure compared to that observed on administration in the fasted state.
Uporaba kombinacije 4 mg/4 mg s hrano je povzročila povečanje izpostavljenosti glimepiridu v primerjavi z uporabo na tešče.
oestrogens and progestagens, saluretics, thiazide diuretics, thyroid stimulating agents, glucocorticoids, phenothiazine derivatives, chlorpromazine, adrenaline and sympathicomimetics, nicotinic acid (high dosages) and nicotinic acid derivatives,
estrogeni in progestogeni, saluretiki, tiazidni diuretiki, sredstva, ki stimulirajo ščitnico, glukokortikoidi, fenotiazinski derivati, klorpromazin, adrenalin in simpatikomimetiki, nikotinska kislina (veliki odmerki) in derivati nikotinske kisline,
Frequency of adverse reaction by treatment regimen Rosiglitazone monotherapy Rosiglitazone with sulphonylurea
Pogostnost neželenega učinka glede na režim zdravljenja Rosiglitazon kot monoterapija Rosiglitazon s sulfonilsečnino
Treatment of patients with G6PD-deficiency with sulphonylurea agents can lead to haemolytic anaemia.
Zdravljenje bolnikov, ki imajo pomanjkanje glukoze-6-fosfat-dehidrogenaze (G6PD), z učinkovinami iz skupine sulfonilsečnin lahko vodi do hemolitične anemije.
Plasma protein binding of rosiglitazone is high (approximately 99.8%) and is not influenced by concentration or age.
Volumen porazdelitve rosiglitazona je pri zdravih prostovoljcih približno 14 l. Vezava rosiglitazona na beljakovine v plazmi je visoka (približno 99,8 %) in koncentracija ali starost nanjo ne vplivata.
Co-administration of rosiglitazone with rifampicin (an inducer of CYP2C8) resulted in a 66% decrease in rosiglitazone plasma concentrations.
Sočasna uporaba rosiglitazona in rifampicina (induktorja CYP2C8) je povzročila 66 % zmanjšanje koncentracije rosiglitazona v plazmi.
Avaglim tablets are a combination of two different medicines called rosiglitazone and glimepiride.
Avaglim tablete vsebujejo kombinacijo dveh zdravilnih učinkovin rosiglitazona in glimepirida.
Limited data are available with regard to overdose of rosiglitazone in humans.
Podatki o prevelikem odmerjanju rosiglitazona pri človeku so omejeni.